Interleukin-2 and interferon-α-2a outpatient therapy for metastatic renal cell carcinoma

Allan Lipton, Harold Harvey, Elise Givant, Kenneth Hopper, Joan Lawler, Yvonne Matthews, March Hirsh, Jacob Zeffren

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


The combination of interleukin-2 (IL-2) and interferon-α-2a (IFN-α- 2a) has synergistic bioactivity in numerous preclinical model systems. Thirty-nine patients with metastatic renal cell cancer were treated with continuous intravenous infusion IL-2 for 4-5 days plus intramuscular IFN-α-2a 2-3 days a week for 4 consecutive weeks. A 2- to 4-week rest period was permitted after each 4 weeks of treatment. Thirty-one of the 39 patients were assessable for response determination. Response rate (six complete + seven partial remissions) was 33.3% for all patients, or 41.9% when the analysis was restricted to the 31 evaluable patients. Three patients were unable to tolerate treatment due to anorexia, weight loss, and severe fatigue. This therapy was relatively well tolerated in the outpatient setting in the other patients despite fever, chills, fatigue, anorexia, and weight loss. There was no correlation of response with site of metastases or bulk of disease.

Original languageEnglish (US)
Pages (from-to)122-129
Number of pages8
JournalJournal of Immunotherapy
Issue number2
StatePublished - Feb 1993

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Interleukin-2 and interferon-α-2a outpatient therapy for metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this